Poll: Will You Recommend Triptorelin to Reproductive-Age Patients With Breast Cancer?

Article

Researchers from Italy have found that premenopausal breast cancer patients treated with triptorelin and chemotherapy were less likely to experience early menopause and were more likely to resume menses than patients who received chemotherapy alone.

 

Researchers from Italy have found that premenopausal breast cancer patients treated with triptorelin and chemotherapy were less likely to experience early menopause and were more likely to resume menses than patients who received chemotherapy alone. The study enrolled 281 premenopausal women across 16 sites; patients in the triptorelin plus chemotherapy group had 3.75 mg doses administered intramuscularly at least 1 week prior to chemotherapy initiation and then every 4 weeks during chemotherapy.

Add your thoughts to our poll.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
Non-hormonal treatments offer relief for genitourinary syndrome of menopause | Image Credit: providers.uthscsa.edu.
Jill Liss, MD, MSCP, FACOG, associate clinical professor, OB/GYN, at the University of Colorado School of Medicine.
© 2025 MJH Life Sciences

All rights reserved.